Arbutus Biopharma
ABUS
99 hedge funds and large institutions have $144M invested in Arbutus Biopharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 16 closing their positions.
60% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $1.09M
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
2.41% more ownership
Funds ownership: 39.87% → 42.28% (+2.4%)
6% less capital invested
Capital invested by funds: $152M → $144M (-$8.59M)
11% less funds holding
Funds holding: 111 → 99 (-12)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Whitefort Capital Management
New York
|
+$7.97M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$4.72M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.73M |
| 4 |
CC
Centiva Capital
New York
|
+$2.25M |
| 5 |
BlackRock
New York
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$7.81M |
| 2 |
Primecap Management
Pasadena,
California
|
-$755K |
| 3 |
Renaissance Technologies
New York
|
-$739K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$585K |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$331K |
ABUS Hedge Fund Activity: Q3 2023 in Review
99 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2023, worth a combined $144M — down 5.6% from $152M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ABUS and 5 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 36 added.
The largest buyer was Whitefort Capital Management, adding an estimated $7.97M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $7.81M sold.
- 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2023, down from 111 in Q2 2023.
- Funds reported $144M of Arbutus Biopharma stock for Q3 2023, down 5.6% quarter-over-quarter.
- 5 funds opened new Arbutus Biopharma positions in Q3 2023 and 16 closed out, a net change of -11 holders.
- The largest Arbutus Biopharma buyer in Q3 2023 was Whitefort Capital Management, an estimated $7.97M added.
- The largest Arbutus Biopharma seller in Q3 2023 was Rubric Capital Management (New York), an estimated $7.81M sold.
Based on aggregated 13F filings for Q3 2023.